Plasma miRNA Profiles in Chronically Treated Bipolar Disorder Patients: A Case-Control Study

Area of Science:

• Biochemistry
• Genetics
• Neuroscience

Background:

• Bipolar disorder (BD) is a complex mood disorder with significant unmet needs in diagnosis and treatment monitoring.
• Pharmacotherapy is the cornerstone of BD management, but understanding its molecular effects remains crucial.

Purpose of the Study:

• To investigate the molecular changes associated with chronic pharmacotherapy in bipolar disorder.
• To identify potential plasma-based microRNA (miRNA) biomarkers for bipolar disorder.

Main Methods:

• Compared plasma miRNA expression profiles of 40 patients with bipolar disorder (on medication for ≥1 year) and 40 healthy controls.
• Quantified 34 specific miRNAs using real-time PCR on the Biomark Real-Time PCR Dynamic Array™ IFC platform.

Main Results:

• Significantly decreased levels of hsa-miR-222-3p, hsa-miR-574-3p, hsa-miR-145-5p, and hsa-miR-195-5p in patients with bipolar disorder.
• Significantly increased levels of hsa-miR-92a-3p (fold change 1.25) and hsa-miR-486-5p (fold change 1.67) in the bipolar disorder group.
• hsa-miR-25-3p also showed an increase, though other miRNAs with raw p < 0.05 lost significance after correction.

Conclusions:

• Peripheral plasma miRNA profiles in chronic bipolar disorder patients reveal distinct expression patterns.
• Elevated miR-92a-3p and miR-486-5p, and decreased miR-222-3p, miR-574-3p, miR-145-5p, and miR-195-5p are potential minimally invasive biomarker candidates.
• Further research is warranted to explore the clinical utility of these miRNAs in bipolar disorder diagnosis, prognosis, and treatment monitoring.